drugset
drugset / Trial / NCT05476380

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT05476380 ↗

Phase 2 Unknown 39 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma

Timeline

Start
2021-02-19
Primary completion
2022-12-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications

carcinoma of esophagus